Hartnell Nicole R, Flanagan Priti S, MacKinnon Neil J, Bakowsky Volodko S
Dalhousie University, Halifax, Nova Scotia, Canada.
Am J Geriatr Pharmacother. 2004 Sep;2(3):171-80. doi: 10.1016/j.amjopharm.2004.09.001.
Two different strategies, referred to as gastrointestinal (GI) preventive therapy (GIPT), have been recommended for high-risk patients to prevent GI complications associated with antiarthritic therapy with nonsteroidal anti-inflammatory drugs (NSAIDs): (1) use of a gastroprotective agent (GPA) along with the NSAID or (2) use of a cyclooxygenase-2-selective inhibitor (COX-2SI). The COX-2SIs rofecoxib and celecoxib have been shown to be as effective as traditional NSAADs for pain relief, but with an improved GI safety profile.
The purpose of this study was to examine the utilization of GIPT by elderly persons in Nova Scotia who were taking antiarthritic medications and to identify the factors associated with their use of GIPT.
A retrospective, cross-sectional study was conducted using administrative data from the Nova Scotia Seniors' Pharmacare Program database. Study participants were aged >or=65 years and had filled a prescription for a COX-2SI, a traditional NSAID, or high-dose aspirin at some point between January 1, 2001 and August 31, 2002. Subjects with at least 1 risk factor (as defined by our study) who received GIPT were classified as receiving appropriate therapy. Subjects with risk factors who did not receive GIPT were classified as potential underutilizers of GIPT. Subjects without risk factors who received GIPT were classified as potential overutilizers of GIPT. Descriptive statistics were presented, and factors independently associated with receiving GIPT were assessed using logistic regression.
The study included 14,587 seniors: 3647 used COX-2SIs, 9412 used traditional NSAIDs alone, and 1528 used traditional NSAADs plus a GPA. Subjects were predominantly female (age range, 65-74 years). In subjects with at least 1 risk factor, 63% were classified as potential underutilizers of GIPT. Thirty-three percent of subjects with no risk factors were classified as potential overutilizers of GIPT. Factors significantly associated with receiving a GIPT included Female gender, annual income >$50,000, urban residence, age >or=75 years, GI complication in the previous year, and concomitant use of warfarin or corticosteroids.
Potential under utilization of GIPT in this subject population was more prevalent than potential overutilization of GIPT. Although all hypothesized risk factors were significantly associated with receiving GIPT, physician education on GI risk factors might improve prescribing of GIPT for elderly persons in Nova Scotia.
对于使用非甾体抗炎药(NSAIDs)进行抗关节炎治疗的高危患者,推荐了两种不同的策略,即胃肠道(GI)预防性治疗(GIPT):(1)将胃保护剂(GPA)与NSAIDs一起使用;(2)使用环氧化酶-2选择性抑制剂(COX-2SI)。已证明COX-2SIs罗非昔布和塞来昔布在缓解疼痛方面与传统NSAIDs一样有效,但胃肠道安全性有所改善。
本研究的目的是调查新斯科舍省服用抗关节炎药物的老年人对GIPT的使用情况,并确定与他们使用GIPT相关的因素。
使用新斯科舍省老年人药物护理计划数据库中的管理数据进行了一项回顾性横断面研究。研究参与者年龄≥65岁,在2001年1月1日至2002年8月31日期间的某个时间点开具了COX-2SI、传统NSAID或高剂量阿司匹林的处方。至少有1个风险因素(根据我们的研究定义)且接受GIPT的受试者被归类为接受适当治疗。有风险因素但未接受GIPT的受试者被归类为GIPT的潜在未充分利用者。没有风险因素但接受GIPT的受试者被归类为GIPT的潜在过度使用者。给出了描述性统计数据,并使用逻辑回归评估了与接受GIPT独立相关的因素。
该研究纳入了14587名老年人:3647人使用COX-2SIs,9412人仅使用传统NSAIDs,1528人使用传统NSAIDs加GPA。受试者主要为女性(年龄范围65 - 74岁)。在至少有1个风险因素的受试者中,63%被归类为GIPT的潜在未充分利用者。没有风险因素的受试者中有33%被归类为GIPT的潜在过度使用者。与接受GIPT显著相关的因素包括女性、年收入>50000美元、城市居住、年龄≥75岁、上一年有胃肠道并发症以及同时使用华法林或皮质类固醇。
在该受试者群体中,GIPT的潜在未充分利用比潜在过度利用更为普遍。尽管所有假设的风险因素都与接受GIPT显著相关,但对医生进行胃肠道风险因素教育可能会改善新斯科舍省老年人GIPT的处方情况。